In addition, targets on other DNA damage repair kinases, which are not discussed in detail in this section but described in our previously published review, such as ATR, CHK1 and WEE1, are being investigated for clinical application in cancers, making them potential new cancer chemotherapy agents in the future. The gene discussed is ATR; the disease is cancer.